Copyright
©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. Feb 14, 2005; 11(6): 899-902
Published online Feb 14, 2005. doi: 10.3748/wjg.v11.i6.899
Published online Feb 14, 2005. doi: 10.3748/wjg.v11.i6.899
Table 2 Comparison of clinical biochemical data and MELD score between PE group and non-PE group before treatment (mean±SD).
| 20 ≤MELD<30 | 30 ≤MELD<40 | MELD≥40 | ||||
| PE group | Non-PE group | PE group | Non-PE group | PE group | Non-PE group | |
| Bilirubin (mmol/L) | 561.66±148.92 | 463.28±169.69 | 606.40±150.60 | 526.44±148.00 | 600.77±140.90 | 677.79±221.18 |
| INR | 2.13±0.62 | 2.34±0.67 | 3.54±1.16 | 4.14±1.24 | 4.01±1.58 | 3.58±1.69 |
| Creatinine (mmol/L) | 70.53±18.69 | 72.51±26.11 | 106.45±37.31 | 101.97±65.85 | 237.12±136.64 | 523.01±289.10 |
| MELD score | 24.7±3.1 | 24.2±3.0 | 34.7±2.2 | 32.4±7.1 | 42.7±1.7 | 48.6±5.3 |
- Citation: Weng ZH, Cai SQ. Analysis of prognosis on patients with severe viral hepatitis using the model for end-stage liver disease. World J Gastroenterol 2005; 11(6): 899-902
- URL: https://www.wjgnet.com/1007-9327/full/v11/i6/899.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i6.899